Inactivation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by gaseous ozone treatment.

Yano, H; Nakano, R; Suzuki, Y; Nakano, A; Kasahara, K; Hosoi, H

Yano, H; Nakano, R; Suzuki, Y; Nakano, A; Kasahara, K; Hosoi, H.

Yano H; Department of Microbiology and Infectious Diseases, Nara Medical University, Nara, Japan.
Nakano R; Department of Microbiology and Infectious Diseases, Nara Medical University, Nara, Japan. Electronic address: rnakano@naramed-u.ac.jp.
Suzuki Y; Department of Microbiology and Infectious Diseases, Nara Medical University, Nara, Japan.
Nakano A; Department of Microbiology and Infectious Diseases, Nara Medical University, Nara, Japan.
Kasahara K; Center for Infectious Diseases, Nara Medical University, Nara, Japan.
Hosoi H; MBT (Medicine-Based Town) Institute, Nara Medical University, Nara, Japan.

J Hosp Infect ; 106(4): 837-838, 2020 12.

Article in English | MEDLINE | ID: covidwho-846751

Subject(s)

COVID-19/prevention & control; Gases/pharmacology; Ozone/pharmacology; SARS-CoV-2/chemistry; COVID-19/diagnosis; COVID-19/epidemiology; COVID-19/virology; Disinfection/methods; Humans; SARS-CoV-2/genetics; SARS-CoV-2/growth & development; Treatment Outcome

Keywords

Inactivation; Ozone; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Ozone / Gases / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Observational study / Prognostic study Limits: Humans Language: English Journal: J Hosp Infect Year: 2020 Document Type: Article Affiliation country: J.jhin.2020.10.004

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google